Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
作者： Eliot Ohlstein , Stephen Caltabiano , Stewart McCallum
DOI:
关键词:
摘要: Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and muscarinic antagonist, methods for their use are disclosed. Disclosed include solabegron oxybutynin. Methods of using the pharmaceutical treatment one or more symptoms associated with overactive bladder, example, frequency urgency, nocturia, urinary incontinence, also
lens.org 参考文章(28)
Scott D. Edmondson, Bart H. Harper, Richard Berger, Novel beta 3 adrenergic receptor agonists ,(2011)
James I. Gillespie, Stefano Palea, Veronique Guilloteau, Marc Guerard, Philippe Lluel, Cees Korstanje, Modulation of non‐voiding activity by the muscarinergic antagonist tolterodine and the β3‐adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction BJUI. ,vol. 110, ,(2012) , 10.1111/J.1464-410X.2012.11240.X
Antonio Scilimati, Ernesto Santandrea, Maria Grazia Perrone, Beta-3 receptor ligands and their use in therapy ,(2007)
Chengzhi Zhang, Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor ,(2010)
Karin Juliette van Charldorp, Monique Maria Alida Klaver, Tennis Edwin Drogendijk, Alberto Garcia Hernandez, Brigitte Johanna Fanny Bosman, Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent ,(2009)
Dominick Anthony Quagliato, William Ronald Solvibile, Albert John Molinari, Mark Anthony Ashwell, Heterocyclic beta-3 adrenergic receptor agonists ,(2001)
Kohei Ogawa, Hiroshi Umeno, Novel remedies with the use of beta 3 agonist ,(2001)
Ursula Ebinger, Marion Wienrich, Martin Michel, Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor ,(2004)